Leuprostin (Leuprorelin)

Leuprorelin mimics natural GnRH and binds to pituitary GnRH receptors. After an initial hormone surge, it desensitises the receptors, leading to a sustained fall in luteinising hormone (LH) and follicle‑stimulating hormone (FSH). This suppresses downstream testosterone and estrogen production, which slows or halts growth of hormone‑sensitive tissues.

The specific dose and dosing interval of Leuprostin are determined by the prescribing clinician based on the patient’s condition, disease stage, and individual response. Dosage regimens may vary widely, and the prescriber will tailor the therapy to achieve optimal hormone suppression while monitoring safety.

Leuprostin’s safety in pregnancy and lactation has not been established. Because it suppresses sex hormone production, it is generally contraindicated in pregnant or nursing women unless the potential benefit outweighs the risk and a specialist advises otherwise.

To request Leuprostin, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Leuprostin, like other GnRH agonists, provides potent suppression of gonadotropins and downstream sex steroids. Compared with GnRH antagonists, it may cause an initial hormone surge before suppression. Relative to surgical or radiotherapy options, it offers a reversible, medical approach, but choice depends on disease specifics, patient preference, and physician assessment.

Leuprostin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided by the manufacturer to maintain product stability.

Leuprostin is administered by subcutaneous injection, typically by a healthcare professional. The injection site is usually the abdomen or thigh. Proper aseptic technique, correct needle length, and rotation of injection sites are important to minimise local reactions and ensure accurate dosing.

Serious risks include significant bone loss leading to osteoporosis, cardiovascular events such as myocardial infarction or stroke, severe allergic reactions including anaphylaxis, and rare cases of pituitary apoplexy. Patients should be monitored regularly for these complications, and any concerning symptoms reported promptly to a clinician.

Leuprostin is contraindicated in individuals with known hypersensitivity to leuprorelin or any component of the formulation. It should be used with caution, or avoided, in patients with severe liver disease, uncontrolled cardiovascular disease, active bone‑metastatic cancers, or in women who are pregnant or breastfeeding unless clearly indicated.